Alkem Laboratories Ltd Share Price
(ALKEM)
₹5033.2
as on 04:01PM, 25 Mar 2025
Alkem Performance
Day's Low
Day's High
₹4,938.8Day's Price Range₹5,09052 Week's Low
52 Week's High
₹4,407.0552-Week Price Range₹6,439.9
| Returns % | |
| 1 Month Return | + 10.71 % |
| 3 Month Return | -6.58 % |
| 1 Year Return | + 1.01 % |
| Market Stats | |
| Previous Close | ₹5,052.55 |
| Open | ₹5,087.00 |
| Volume | 84.34K |
| Upper Circuit | ₹5,557.80 |
| Lower Circuit | ₹4,547.30 |
| Market Cap | ₹60,410.81Cr |
Alkem Fundamentals
P/E Ratio
28.06
PEG Ratio
0.58
Market Cap
₹60,410.81 Cr
P/B Ratio
5.6
EPS
151.52
Dividend Yield
0.81
Sector
Pharmaceuticals
ROE
17.56
Mutual Fund Holdings of Alkem
Alkem Analyst Rating
based on 21 analysts
42.86%
Buy
23.81%
Hold
33.33%
Sell
Based on 21 analysts offering long term price targets for Alkem. An average target of ₹5384.52
Source: S&P Global Market Intelligence
Alkem Share analysis
Alkem price forecast by 21 analysts
Upside of6.57%
High
₹6642
Target
₹5384.52
Low
₹4186
Alkem target price ₹5384.52, a slight upside of 6.57% compared to current price of ₹5033.2. According to 21 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alkem revenue growth forecast
Expected growth rate Q1, FY2027:24.07%
Forecast
Actual
Including amortisation and stock based compensations
Alkem EPS growth forecast
EPS estimate Q1, FY2027:46.47%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Alkem Laboratories Ltd
Alkem Laboratories Receives Positive FDA Inspection Results - 17 Mar, 2025
Alkem Laboratories successfully cleared a USFDA inspection at its Bioequivalence Center, leading to a positive market response. Analysts suggest a buy rating, and the company plans to launch semaglutide by 2026.Alkem Expands Portfolio and Passes USFDA Inspection - 15 Mar, 2025
Alkem Laboratories announced a strategic acquisition of Bombay Ortho Industries and successfully cleared a USFDA inspection at its Bioequivalence Center, despite a slight decline in Q3 profits.Alkem Launches New Drug, Passes FDA Inspection - 13 Mar, 2025
Alkem Laboratories launched a generic medication for chronic conditions and received a positive outcome from a US FDA inspection, confirming regulatory compliance.Alkem Launches Affordable Generic Empagliflozin in India - 12 Mar, 2025
Alkem Laboratories has launched a generic version of empagliflozin, named Empanorm, at approximately 80% lower prices than innovator products. The launch includes anti-counterfeit measures and patient education materials, enhancing accessibility for diabetes and chronic kidney disease treatments.Alkem Appoints New Senior Management Personnel - 10 Mar, 2025
Alkem Laboratories has appointed Shirish Purushotham Ambulgekar to a senior management position, effective March 10, 2025. The company also reported a 1.91% decline in share price.CDSCO Lists Alkem Drugs as Not of Standard Quality - 01 Mar, 2025
The Central Drugs Standard Control Organisation has flagged select batches of 145 drugs, including Alkem's Ondem-4 tablets, as not of standard quality for January 2025.Alkem Laboratories Faces ₹62 Cr GST Demand - 28 Feb, 2025
Alkem Laboratories has received a ₹62 crore GST demand for the fiscal years 2020-2021 and 2021-2022, alleging incorrect GST liability payments. The company plans to contest the order.Nomura Upgrades Alkem Labs Amid Challenges - 27 Feb, 2025
Nomura has upgraded Alkem Labs to a Buy rating, despite lowering its target price to ₹5,430 due to growth concerns and recent underperformance. The brokerage sees long-term growth potential from strategic investments, suggesting the stock's current valuation presents an attractive buying opportunity.SBI Mutual Fund Expands Stake Amid Share Decline - 21 Feb, 2025
On February 21, 2025, Alkem Laboratories shares fell after a large Rs 300 crore deal. SBI Mutual Fund increased its stake to 2.7% through additional purchases.
Insights on Alkem Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 16.10% to 16.18% in Dec 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 9.02% to 10.15% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, ALKEM stock has moved up by 10.7%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 55.66% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 138.5% return, outperforming this stock by 99.0%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 74.3% return, outperforming this stock by 73.3%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 688.64 Cr → 625.82 Cr (in ₹), with an average decrease of 9.1% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 14.94% to 14.01% in Dec 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 3.54K Cr → 3.46K Cr (in ₹), with an average decrease of 2.3% per quarter
Alkem Financials
Alkem Index Inclusions
Alkem Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 55.66% | 0.00 | |
| Foreign Institutions | 10.15% | 12.45 | |
| Mutual Funds | 14.01% | ||
| Retail Investors | 16.18% | 0.47 | |
| Others | 4% |
Alkem Key Indicators
Alkem Valuation
Alkem in the last 5 years
Lowest (20.07x)
March 24, 2021
Today (28.06x)
March 24, 2025
Industry (53.98x)
March 24, 2025
Highest (44.21x)
August 9, 2023
Alkem Earnings and Dividends
Alkem Laboratories Ltd Earnings Results
Alkem Laboratories Ltd’s net profit jumped 5.19% since last year same period to ₹625.82Cr in the Q3 2024-2025. On a quarterly growth basis, Alkem Laboratories Ltd has generated -9.12% fall in its net profits since last 3-months.
Read More about Earnings ResultsAlkem Laboratories Ltd Dividends February,2025
In the quarter ending December 2024, Alkem Laboratories Ltd has declared dividend of ₹37 - translating a dividend yield of 1.53%.
Read More about Dividends
Alkem Technicals Summary
Bearish
Neutral
Bullish
Alkem Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.
Alkem Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹60,410.81 Cr | 24.44% | 0.56 | ₹1,811 Cr | ₹12,667 Cr | |
| HOLD | ₹20,818.10 Cr | 15.6% | 0.55 | ₹362 Cr | ₹2,226 Cr | |
| HOLD | ₹33,595.43 Cr | 171.63% | 0.67 | ₹168 Cr | ₹5,040 Cr | |
| BUY | ₹10,757.82 Cr | 13.81% | 0.64 | ₹119 Cr | ₹547 Cr | |
| BUY | ₹3,895.55 Cr | 8.38% | 0.54 | ₹69 Cr | ₹571 Cr |
About Alkem
With its headquarters in Mumbai, India, Alkem Laboratories is engaged in the manufacture of a wide range of pharmaceutical products across multiple therapeutic categories, including cardiovascular, central nervous system, gastro-intestinal, anti-infective, diabetology, and nutrition. The company has a strong presence in the Indian market and exports its products to over 50 countries.
Revenue: ₹3,374.28Cr as on December 2024 (Q4 24)
Net Profit: ₹640.79Cr as on December 2024 (Q4 24)
Listing date: 23 Dec, 2015
Chairperson Name: Basudeo N Singh
| Organisation | Alkem |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Alkem Laboratories Ltd
What is Alkem Laboratories Ltd price today?
Alkem Laboratories Ltd share price today stands at ₹5033.2, Open: ₹5087, Previous Close: ₹5052.55, High: ₹5090, Low: ₹4938.8, 52 Week High: ₹6439.9, 52 Week Low: ₹4407.05.
How to Buy Alkem Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Alkem Laboratories Ltd shares
What are today's traded volumes of Alkem Laboratories Ltd?
Today's traded volume of Alkem Laboratories Ltd(ALKEM) is 84.34K.
What is today's market capitalisation of Alkem Laboratories Ltd?
Today's market capitalisation of Alkem Laboratories Ltd(ALKEM) is ₹60410.81Cr.
What is the 52 Week High and Low Range of Alkem Laboratories Ltd?
How much percentage Alkem Laboratories Ltd is down from its 52 Week High?
Alkem Laboratories Ltd (ALKEM) share price is ₹5033.2. It is down -21.84% from its 52 Week High price of ₹6439.9
How much percentage Alkem Laboratories Ltd is up from its 52 Week low?
Alkem Laboratories Ltd (ALKEM) share price is ₹5033.2. It is up 14.21% from its 52 Week Low price of ₹4407.05